Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.64 |
| ▸ | GSK3B | P49841 | 10/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | GPR39 | O43194 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13304765 | 0.91 | CDK2 (0.77) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL12952873 | 0.88 | CDK2 (0.83) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13146486 | 0.88 | CDK2 (0.79) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13304785 | 0.85 | CDK2 (0.61) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13305604 | 0.84 | GSK3B (0.59) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL13305161 | 0.82 | GSK3B (0.56) | CDK2GSK3BCCNA2CCNA1GPR39 | |
| SCHEMBL12953665 | 0.82 | GSK3B (0.63) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL14043290 | 0.81 | GSK3B (0.60) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL14050973 | 0.81 | GSK3B (0.62) | CDK2GSK3BCCNA2CCNA1CCNE1 | |
| SCHEMBL14050780 | 0.81 | GSK3B (0.60) | CDK2GSK3BCCNA2CCNA1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |